UK Markets closed

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
14.31-0.87 (-5.73%)
At close: 04:59PM CET
Full screen
Previous close15.18
Open15.19
Bid14.35 x 0
Ask14.51 x 0
Day's range14.01 - 15.20
52-week range14.01 - 109.10
Volume110,082
Avg. volume134,945
Market cap500.166M
Beta (5Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-25.55
Earnings date15 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est136.50
  • Globe Newswire

    Orphazyme updates 2021 financial outlook

    Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No. 32266355 Net revenue range narrowed to DKK 35 – 37 millionOperating expenses lowered to DKK 665 – 675 million, due to strict cost managementCash position as of December 31, 2021, now anticipated to be no less than DKK 100 million Copenhagen – January 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces an update to its financial outlook for 2021 b

  • Globe Newswire

    Orphazyme announces changes to the Board of Directors

    Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021. Orphazyme has appointed Andrew Mercieca as Observer and Consultant to the Board of Directors with the intention that he will be proposed as a member of t

  • Zacks

    All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

    Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.